Evidence map›Paper›PMID 41836299›Full record

ReviewFrontiers in cell and developmental biology2026

Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy.

Jakob Steuer, Abdullah Kahraman

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jakob SteuerData Science in Life Sciences Group, Institute for Chemistry and Bioanalytics, School of Life Sciences, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.
Abdullah KahramanData Science in Life Sciences Group, Institute for Chemistry and Bioanalytics, School of Life Sciences, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spliceosome is a dynamic molecular machine essential for transcriptome diversity, yet its complexity creates specific vulnerabilities in cancer. Recurrent somatic mutations in core factors, particularly SF3B1, U2AF1, and SRSF2, drive malignancies by altering splice-site recognition. Such structural perturbations do not merely drive oncogenesis but manifest as distinctive molecular signatures that can serve as potent diagnostic and prognostic biomarkers. However, therapeutic exploitation of these defects remains challenging. This review argues that unlocking the spliceosome requires a shift from static cryo-EM snapshots to dynamic structural ensembles. We explore how physics-based molecular simulation and enhanced sampling methods are merging with generative Artificial Intelligence to identify intermediate states, map cryptic allosteric pockets and target intrinsically disordered regions. Translating these mechanistic insights into the clinic, we evaluate the next-generation of therapeutic strategies, ranging from novel molecular biomarkers to rationally designed allosteric modulators and synthetic lethality. Finally, we discuss how deciphering these altered structural dynamics can guide the identification of splicing-derived neoantigens and biomarkers, establishing a roadmap for precision immunotherapy.

Indexed as

biomarkercancergenerative AImolecular dynamicsneoantigensspliceosome

Identifiers

PMID41836299
PMCPMC12982372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.